Literature DB >> 7616415

Flecainide inhibits the transient outward current in atrial myocytes isolated from the rabbit heart.

T Yamashita1, T Nakajima, E Hamada, H Hazama, M Omata, Y Kurachi.   

Abstract

We examined the effects of flecainide, a class Ic antiarrhythmic agent, on membrane currents in single rabbit atrial myocytes, using the tight-seal whole cell voltage-clamp technique. Under the current-clamp condition, flecainide (1-100 microM) prolonged the action potential duration at both the early and the late phases of repolarization in a concentration-dependent manner without affecting the resting membrane potential. In the presence of 4-aminopyridine, however, the drug affected the atrial action potential duration differently than it did in the absence of 4-aminopyridine: it shortened the early phase and only slightly lengthened the late phase of the atrial action potential. Under the voltage-clamp condition, flecainide suppressed the 4-amino-pyridine-sensitive, Ca(++)-insensitive transient outward current in a concentration-dependent fashion (the concentration for the half-maximal effect was approximately 17 microM). The drug also slightly inhibited the voltage-dependent L-type Ca++ current and delayed outward K+ current. Flecainide apparently accelerated the inactivation time course of the transient outward current but did not affect the voltage-dependence of its steady-state inactivation. These actions of flecainide on the transient outward current could be described by a voltage-dependent first-order interaction of the drug with the channel.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616415

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Functional Characterization of Human Stem Cell-Derived Cardiomyocytes.

Authors:  Glenn E Kirsch; Carlos A Obejero-Paz; Andrew Bruening-Wright
Journal:  Curr Protoc Pharmacol       Date:  2014

2.  A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms.

Authors:  Jonathan D Moreno; Z Iris Zhu; Pei-Chi Yang; John R Bankston; Mao-Tsuen Jeng; Chaoyi Kang; Lianguo Wang; Jason D Bayer; David J Christini; Natalia A Trayanova; Crystal M Ripplinger; Robert S Kass; Colleen E Clancy
Journal:  Sci Transl Med       Date:  2011-08-31       Impact factor: 17.956

3.  Molecular and pharmacological characteristics of transient voltage-dependent K+ currents in cultured human pulmonary arterial smooth muscle cells.

Authors:  Haruko Iida; Taisuke Jo; Kuniaki Iwasawa; Toshihiro Morita; Hisako Hikiji; Tsuyoshi Takato; Teruhiko Toyo-Oka; Ryozo Nagai; Toshiaki Nakajima
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

4.  Why Is Only Type 1 Electrocardiogram Diagnostic of Brugada Syndrome? Mechanistic Insights From Computer Modeling.

Authors:  Zhaoyang Zhang; Peng-Sheng Chen; James N Weiss; Zhilin Qu
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-12-29

5.  Dihydropyridine Ca2+ channel antagonists and agonists block Kv4.2, Kv4.3 and Kv1.4 K+ channels expressed in HEK293 cells.

Authors:  Noriyuki Hatano; Susumu Ohya; Katsuhiko Muraki; Wayne Giles; Yuji Imaizumi
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

6.  Effects of development and thyroid hormone on K+ currents and K+ channel gene expression in rat ventricle.

Authors:  A D Wickenden; R Kaprielian; T G Parker; O T Jones; P H Backx
Journal:  J Physiol       Date:  1997-10-15       Impact factor: 5.182

7.  Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.

Authors:  Ashok A Paul; Harry J Witchel; Jules C Hancox
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.